Streetbeat News

Stock Prices

COUR

Coursera shares are trading higher after the company beat Q2 earnings estimates.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 12:19 pm

NWFL

Norwood Financial (NASDAQ:NWFL) reported a significant decrease in its Q2 earnings per share (EPS), down 35.8% from $0.81 to $0.52 year-over-year.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 12:17 pm

BABA

META

NVDA

Alibaba and Tencent have integrated Meta's latest AI model, Llama 3.1, into their cloud services. This move comes amid strained U.S.-China relations and advanced semiconductor sanctions. Alibaba's stock has been under pressure, losing over 22% in the last 12 months.

Portfolio Pulse from Anusuya Lahiri

July 26, 2024 | 12:15 pm

BMY

Bristol Myers Squibb (NYSE:BMY) reported strong Q2 earnings, with revenues of $12.20 billion, beating expectations. The growth was driven by newer drugs like Opdivo and Eliquis. The company raised its 2024 profit forecast and expects revenue growth at the upper end of the low single-digit range.

Portfolio Pulse from Vandana Singh

July 26, 2024 | 12:08 pm

CRI

DXCM

INDV

MGNX

OLN

TNDM

URG

ZYXI

Several major stocks, including DexCom, Zynex, Olin, and others, are experiencing significant declines in Friday's pre-market session. DexCom's shares fell sharply due to worse-than-expected Q2 revenue and weak FY24 guidance. Other companies like Zynex, Ur-Energy, Tandem Diabetes Care, MacroGenics, Olin Corporation, Carter’s, and Indivior also saw declines due to various financial results and announcements.

Portfolio Pulse from Avi Kapoor

July 26, 2024 | 12:05 pm

PFC

Trading for PFC was halted at 8:05:00 a.m. ET due to pending news. Investors should stay tuned for further updates.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 12:05 pm

BC

DXCM

HBAN

LHX

LUV

Top Wall Street analysts have downgraded several notable stocks, including L3Harris Technologies, Huntington Bancshares, Southwest Airlines, Brunswick Corporation, and DexCom. These downgrades come with adjusted price targets, reflecting changes in analyst sentiment.

Portfolio Pulse from Avi Kapoor

July 26, 2024 | 12:04 pm

GNTX

Gentex Corporation has revised its FY14 revenue outlook downward from the previous range of $2.45 billion - $2.55 billion to a new range of $2.40 billion - $2.50 billion, compared to the $2.45 billion estimate.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 12:04 pm

DXCM

Dexcom Inc. (NASDAQ:DXCM) shares plummeted nearly 39% in pre-market trading after the company lowered its full-year sales outlook for glucose monitoring devices. The revised revenue forecast for 2024 is now between $4 billion and $4.05 billion, down from the previous estimate of $4.2 billion to $4.35 billion. The forecast cut is attributed to fewer new customers, lower revenue per customer, and higher rebates due to changes in reimbursement methods by large health plans. Despite these challenges, CEO Kevin Sayer remains confident in the company's long-term targets for 2025.

Portfolio Pulse from Benzinga Neuro

July 26, 2024 | 12:03 pm

GENE

Genetic Technologies Limited (NASDAQ: GENE) is transitioning to a capital light operating model to reduce costs and focus on sales growth in the US. The company will outsource operations and has secured a short-term $800,000 loan to fund working capital. EasyDNA sales are growing, reaching $7M.

Portfolio Pulse from Benzinga Newsdesk

July 26, 2024 | 12:03 pm